174 related articles for article (PubMed ID: 30374123)
1. WT1 expression in vessels varies with histopathological grade in tumour-bearing and control tissue from patients with breast cancer.
McGregor RJ; Chau YY; Kendall TJ; Artibani M; Hastie N; Hadoke PWF
Br J Cancer; 2018 Dec; 119(12):1508-1517. PubMed ID: 30374123
[TBL] [Abstract][Full Text] [Related]
2. Correlation of Wilms' tumor 1 isoforms with HER2 and ER-α and its oncogenic role in breast cancer.
Nasomyon T; Samphao S; Sangkhathat S; Mahattanobon S; Graidist P
Anticancer Res; 2014 Mar; 34(3):1333-42. PubMed ID: 24596380
[TBL] [Abstract][Full Text] [Related]
3. Expression of tumor-associated antigens in breast cancer subtypes.
Curigliano G; Bagnardi V; Ghioni M; Louahed J; Brichard V; Lehmann FF; Marra A; Trapani D; Criscitiello C; Viale G
Breast; 2020 Feb; 49():202-209. PubMed ID: 31869767
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors affecting disease-free survival rate following surgical resection of primary breast cancer.
Horita K; Yamaguchi A; Hirose K; Ishida M; Noriki S; Imamura Y; Fukuda M
Eur J Histochem; 2001; 45(1):73-84. PubMed ID: 11411868
[TBL] [Abstract][Full Text] [Related]
5. Tumour-associated endothelial-FAK correlated with molecular sub-type and prognostic factors in invasive breast cancer.
Alexopoulou AN; Ho-Yen CM; Papalazarou V; Elia G; Jones JL; Hodivala-Dilke K
BMC Cancer; 2014 Apr; 14():237. PubMed ID: 24693876
[TBL] [Abstract][Full Text] [Related]
6. The Wilms' tumor suppressor WT1 induces estrogen-independent growth and anti-estrogen insensitivity in ER-positive breast cancer MCF7 cells.
Wang L; Wang ZY
Oncol Rep; 2010 Apr; 23(4):1109-17. PubMed ID: 20204298
[TBL] [Abstract][Full Text] [Related]
7. The Wilms' tumor suppressor WT1 regulates expression of members of the epidermal growth factor receptor (EGFR) and estrogen receptor in acquired tamoxifen resistance.
Wang L; Zhang X; Wang ZY
Anticancer Res; 2010 Sep; 30(9):3637-42. PubMed ID: 20944147
[TBL] [Abstract][Full Text] [Related]
8. Differential expression of immunohistochemical markers in primary lung and breast cancers enriched for triple-negative tumours.
Provenzano E; Byrne DJ; Russell PA; Wright GM; Generali D; Fox SB
Histopathology; 2016 Feb; 68(3):367-77. PubMed ID: 26118394
[TBL] [Abstract][Full Text] [Related]
9. Wilms' tumor 1 suppressor gene mediates antiestrogen resistance via down-regulation of estrogen receptor-alpha expression in breast cancer cells.
Han Y; Yang L; Suarez-Saiz F; San-Marina S; Cui J; Minden MD
Mol Cancer Res; 2008 Aug; 6(8):1347-55. PubMed ID: 18708366
[TBL] [Abstract][Full Text] [Related]
10. High Wilms' tumor 1 mRNA expression correlates with basal-like and ERBB2 molecular subtypes and poor prognosis of breast cancer.
Qi XW; Zhang F; Yang XH; Fan LJ; Zhang Y; Liang Y; Ren L; Zhong L; Chen QQ; Zhang KY; Zang WD; Wang LS; Zhang Y; Jiang J
Oncol Rep; 2012 Oct; 28(4):1231-6. PubMed ID: 22797561
[TBL] [Abstract][Full Text] [Related]
11. The Wilms' tumour suppressor WT1 is involved in endothelial cell proliferation and migration: expression in tumour vessels in vivo.
Wagner N; Michiels JF; Schedl A; Wagner KD
Oncogene; 2008 Jun; 27(26):3662-72. PubMed ID: 18212735
[TBL] [Abstract][Full Text] [Related]
12. Wilms' tumour protein Wt1 stimulates transcription of the gene encoding vascular endothelial cadherin.
Kirschner KM; Sciesielski LK; Scholz H
Pflugers Arch; 2010 Nov; 460(6):1051-61. PubMed ID: 20811903
[TBL] [Abstract][Full Text] [Related]
13. Coordinated expression of oestrogen and androgen receptors in HER2-positive breast carcinomas: impact on proliferative activity.
Lin Fde M; Pincerato KM; Bacchi CE; Baracat EC; Carvalho FM
J Clin Pathol; 2012 Jan; 65(1):64-8. PubMed ID: 22039288
[TBL] [Abstract][Full Text] [Related]
14. HER2/neu increases the expression of Wilms' Tumor 1 (WT1) protein to stimulate S-phase proliferation and inhibit apoptosis in breast cancer cells.
Tuna M; Chavez-Reyes A; Tari AM
Oncogene; 2005 Feb; 24(9):1648-52. PubMed ID: 15674342
[TBL] [Abstract][Full Text] [Related]
15. Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study.
Puig-Vives M; Sánchez MJ; Sánchez-Cantalejo J; Torrella-Ramos A; Martos C; Ardanaz E; Chirlaque MD; Perucha J; Díaz JM; Mateos A; Machón M; Marcos-Gragera R
Gynecol Oncol; 2013 Sep; 130(3):609-14. PubMed ID: 23747837
[TBL] [Abstract][Full Text] [Related]
16. Correlations between diffusion-weighted imaging and breast cancer biomarkers.
Martincich L; Deantoni V; Bertotto I; Redana S; Kubatzki F; Sarotto I; Rossi V; Liotti M; Ponzone R; Aglietta M; Regge D; Montemurro F
Eur Radiol; 2012 Jul; 22(7):1519-28. PubMed ID: 22411304
[TBL] [Abstract][Full Text] [Related]
17. Prognostic stratification of oestrogen receptor-positive HER2-negative lymph node-negative class of breast cancer.
Rakha EA; Agarwal D; Green AR; Ashankyty I; Ellis IO; Ball G; Alaskandarany MA
Histopathology; 2017 Mar; 70(4):622-631. PubMed ID: 27782306
[TBL] [Abstract][Full Text] [Related]
18. High expression of Wilms' tumor suppressor gene predicts poor prognosis in breast cancer patients.
Miyoshi Y; Ando A; Egawa C; Taguchi T; Tamaki Y; Tamaki H; Sugiyama H; Noguchi S
Clin Cancer Res; 2002 May; 8(5):1167-71. PubMed ID: 12006533
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic utility of Wilms' tumour-1 protein (WT-1) immunostaining in paediatric renal tumours.
Goyal S; Mishra K; Sarkar U; Sharma S; Kumari A
Indian J Med Res; 2016 May; 143(Supplement):S59-S67. PubMed ID: 27748279
[TBL] [Abstract][Full Text] [Related]
20. Progesterone receptor status in determining the prognosis of estrogen receptor positive/ HER2 negative breast carcinoma patients.
Bal O; Yalcintas Arslan U; Durnali A; Uyetrk U; Demirci A; Tastekin D; Ekinci A; Esbah O; Turker I; Uysal Sonmez O; Oksuzoglu B
J BUON; 2015; 20(1):28-34. PubMed ID: 25778292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
